We understand that GLP-1 has well-known anti-atherosclerotic properties and that treatment with GLP-1 agonists reduces food intake, and thus these drugs are used in the treatment of obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.